Market Overview

What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy

Share:
What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy
Related
Benzinga's Top Upgrades, Downgrades For November 1, 2018
10 Hottest Stocks From October 22, 2018
SELLAS Life Sciences Group, Inc. (SLS) CEO Angelos Stergiou on Q3 2018 Results - Earnings Call Transcript (Seeking Alpha)

Sellas Life Sciences Group Inc (NASDAQ: SLS) popped as much as 189 percent Monday after reporting “clinically meaningful activity” in interim data for its Phase 2b NeuVax trial.

H.C. Wainwright liked the stock before it peaked, though, and it considers NeuVax just a footnote in the bullish narrative.

The Rating

Analyst Joseph Pantginis initiated coverage on Sellas with a Buy rating and $11 price target.

The Thesis

Sellas became public in January in a reverse merger with Galena to advance its galinpepimut-S, a cancer vaccine seen to boast broad potential.

“Overall, since the company is a new entrant to the public markets, we believe a value disconnect currently exists between clinical data in hand and projected catalysts,” Pantginis said in a Monday note.

The analyst considers GPS well-positioned to take on the Wilms’ tumor 1 antigen, which has broad potential in immuno-oncology.

So far, GPS has generated “encouraging” clinical data for multiple tumor indications, with acute myeloid leukemia at the forefront. Sellas recently reported positive Phase 2 data in AML nearly tripling survival in one age group relative to current standards of care. A Phase 2 trial in mesothelioma also demonstrated life extension.

The candidate is currently in a Phase 1/2 study for multiple myeloma and is about to start an ovarian cancer combination study with Bristol-Myers Squibb Co (NYSE: BMY)’s Opdivo.

“We believe SELLAS represents a new name for investors to get their arms around, especially based on the Phase 3 readiness of GPS, and firm footing in the immuno-oncology sandbox," Pantginis said. 

Upcoming catalysts include the launch of a pivotal Phase 3 study in AML and a combination study with Merck & Co., Inc. (NYSE: MRK)’s Keytruda for multiple tumor types later this year.

Price Action

At the time of publication, Sellas was trading up 157 percent at $8.88. 

Related Links:

For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'

Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts

Latest Ratings for SLS

DateFirmActionFromTo
Nov 2018OppenheimerInitiates Coverage OnOutperform
Jul 2018Maxim GroupMaintainsBuyBuy
Apr 2018H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for SLS
View the Latest Analyst Ratings

Posted-In: H.C. WainwrightAnalyst Color Biotech Price Target Initiation Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LXFTKeyBancDowngrades0.0
CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

On World Autism Awareness Day, A Look At Biotech Firms With Potential Treatments In The Pipeline

Mid-Day Market Update: NASDAQ Down Over 2%; SELLAS Life Sciences Shares Spike Higher